Selecta Biosciences, Inc. Long-Term Investments

Long-Term Investments of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-Term Investments growth rates and interactive chart. An accounting item that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year. The long-term investment account differs largely from the short-term investment account in that short-term investments will most likely be sold, whereas the long-term investments will not be sold for years and, in some cases, may never be sold.


Highlights and Quick Summary

  • Long-Term Investments for the quarter ending December 30, 2020 was $1.38 Million (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Long-Term Investments decreased by 0.0%
  • Annual Long-Term Investments for 2020 was $1.38 Million (a 0.0% decrease from previous year)
  • Annual Long-Term Investments for 2019 was $1.38 Million (a 394.27% increase from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-Term Investments of Selecta Biosciences, Inc.

Most recent Long-Term Investmentsof SELB including historical data for past 10 years.

Interactive Chart of Long-Term Investments of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Long-Term Investments for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $1.38 $1.38 $1.38 $1.38 $1.38
2019 $1.38 $1.38
2018 $0.28

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.